Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 6;9(2):20.
doi: 10.3390/ijns9020020.

Implementation of Newborn Screening for Conditions in the United States First Recommended during 2010-2018

Affiliations

Implementation of Newborn Screening for Conditions in the United States First Recommended during 2010-2018

Sikha Singh et al. Int J Neonatal Screen. .

Abstract

The Recommended Uniform Screening Panel (RUSP) is the list of conditions recommended by the US Secretary of Health and Human Services for inclusion in state newborn screening (NBS). During 2010-2022, seven conditions were added to the RUSP: severe combined immunodeficiency (SCID) (2010), critical congenital heart disease (CCHD) (2011), glycogen storage disease, type II (Pompe) (2015), mucopolysaccharidosis, type I (MPS I) (2016), X-linked adrenoleukodystrophy (X-ALD) (2016), spinal muscular atrophy (SMA) (2018), and mucopolysaccharidosis, type II (MPS II) (2022). The adoption of SCID and CCHD newborn screening by programs in all 50 states and three territories (Washington, D.C.; Guam; and Puerto Rico) took 8.6 and 6.8 years, respectively. As of December 2022, 37 programs screen for Pompe, 34 for MPS I, 32 for X-ALD, and 48 for SMA. The pace of implementation based on the average additional number of NBS programs per year was most rapid for SMA (11.3), followed by CCHD (7.8), SCID (6.2), MPS I (5.4), Pompe (4.9), and X-ALD (4.7).

Keywords: new conditions; newborn screening; public health.

PubMed Disclaimer

Conflict of interest statement

The authors declare they have no conflict of competing interest.

Figures

Figure 1
Figure 1
Average Number of Years to Implementation of Conditions Added to RUSP during 2010–2018 for Programs that Completed Implementation by 2022.
Figure 2
Figure 2
Number of Programs Implementing Screening Each Year for SCID (n = 53), CCHD (n = 53), Pompe (n = 37), MPS I (n = 34), X-ALD (n = 32), and SMA (n = 48) as of December 2022 (marker indicates year of addition to RUSP).

References

    1. Watson M.S., Lloyd-Puryear M.A., Howell R.R. The progress and future of US newborn screening. Int. J. Neonatal Screen. 2022;8:41. doi: 10.3390/ijns8030041. - DOI - PMC - PubMed
    1. Watson M.S., Mann M.Y., Lloyd-Puryear M.A., Rinaldo P., Howell R.R. American College of Medical Genetics Newborn Screening Expert Group. Newborn screening: Toward a uniform screening panel and system—Executive summary. Pediatrics. 2006;117((Suppl. S3)):S296–S307. doi: 10.1542/peds.2005-2633I. - DOI - PubMed
    1. Kemper A., Green N., Calonge N., Lam W.K.K., Comeau A., Goldenberg A., Ojodu J., Prosser L.A., Tanksley S., Bocchini J.A. Decision-making process for conditions nominated to the Recommended Uniform Screening Panel: Statement of the US Department of Health and Human Services Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children. Genet. Med. 2014;16:183–187. doi: 10.1038/gim.2013.98. - DOI - PubMed
    1. Calonge N., Green N., Rinaldo P., Lloyd-Puryear M., Dougherty D., Boyle C., Watson M., Trotter T., Terry S., Howell R., et al. Committee report: Method for evaluating conditions nominated for population-based screening of newborns and children. Genet. Med. 2010;12:153–159. doi: 10.1097/GIM.0b013e3181d2af04. - DOI - PubMed
    1. Kemper A.R., Lam W.K.K., Ream M., Lennox A. NBS Implementation for Conditions Added to the RUSP; Proceedings of the ACHDNC Meeting; Rockville, MD, USA. 1 August 2019; [(accessed on 16 December 2022)]. Available online: https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/herita....